Clinical trial registry record

Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 21, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07774000
Last registry update
August 21, 2026
Status
Recruiting
Phase
Phase not reported
Sponsor
ChromaDex, Inc.
Enrollment
140
Countries
South Africa
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · OTHER · QUADRUPLE
Evidence population
Human clinical study registration
Participants
140
Population
FEMALE · 30 Years to 60 Years
Duration
2026-08-17 to 2027-03-31
Intervention
Topical niacinamide riboside; Placebo
Comparator
Placebo
Outcomes measured
Change in skin's biological age — baseline and day 84; Quantitative change in fine lines and wrinkles — baseline and days 28, 56, and 84; Quantitative changes in skin firmness and tightness — baseline and days 56 and 84; Skin hydration — baseline and day 28; Moisture retention — baseline and day 28; Skin barrier integrity — baseline and day 28; Pores — baseline and days 28, 56, and 84; Texture/smoothness — baseline and days 28, 56, and 84; Skin tone evenness — baseline and days 28, 56, and 84; Skin plumpness — baseline and days 28, 56, and 84; Radiance — baseline and days 28, 56, and 84; Redness — baseline and days 28, 56, and 84; Firmness — baseline and days 28, 56, and 84; Participant Reported Outcome: Efficacy and acceptability of product — baseline and days 14, 28, 42, 56, and 84; Adverse Event Monitoring — Up to two weeks after study completion
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Skin ageing · 100%Title contains controlled term: skin aging. Abstract contains controlled term: skin aging. Source terminology contains: skin aging. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.